nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.10.2012 | Research Paper

Stromal biomarkers in breast cancer development and progression

verfasst von: Jenny A. Rudnick, Charlotte Kuperwasser

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is a heterogeneous, multi-factorial disease of aberrant breast development whose etiology relies upon several microenvironmental changes within the tissue. Within the last decade, it has become widely accepted that tumor cells frequently rely on signals from an activated microenvironment in order to proliferate and survive within a tissue. This activated tissue microenvironment involves the appearance of αSMA + fibroblasts (referred to as “cancer associated fibroblasts”), the recruitment of various immune cells (macrophages, T cells, B cells, T regulatory cells), enhanced collagen I deposition, and epigenetic modifications of stromal cells. These stromal changes can predict patient survival and correlate with distinct breast tumor subtypes. Characterizing these stromal changes will facilitate their use as clinical biomarkers in breast cancer, and may facilitate their use as potential drug targets for adjuvant breast cancer therapy.

Mintz B, Illmensee K (1975) Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Nat Acad Sci USA 72(9):3585–3589PubMedCrossRef

Stoker AW, Hatier C, Bissell MJ (1990) The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia. J Cell Biol 111(1):217–228PubMedCrossRef

Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1(1):46–54PubMedCrossRef

Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392–401PubMedCrossRef

Bissell MJ, Radisky DC, Rizki A et al (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70(9–10):537–546PubMedCrossRef

Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650–1659PubMedCrossRef

Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150PubMedCrossRef

Mori L, Bellini A, Stacey MA et al (2005) Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 304(1):81–90PubMedCrossRef

Wixler V, Hirner S, Muller JM et al (2007) Deficiency in the LIM-only protein Fhl2 impairs skin wound healing. J Cell Biol 177(1):163–172PubMedCrossRef

10.

Allinen M, Beroukhim R, Cai L et al (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6(1):17–32PubMedCrossRef

11.

Casey T, Bond J, Tighe S et al (2009) Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 114(1):47–62PubMedCrossRef

12.

Finak G, Bertos N, Pepin F et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527PubMedCrossRef

13.

Ma XJ, Dahiya S, Richardson E et al (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11(1):R7PubMedCrossRef

14.

Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335–348PubMedCrossRef

15.

Erez N, Truitt M, Olson P et al (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17(2):135–147PubMedCrossRef

16.

Hwang RF, Moore T, Arumugam T et al (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68(3):918–926PubMedCrossRef

17.

O’Connell JT, Sugimoto H, Cooke VG et al (2011) VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Nat Acad Sci USA 108(38):16002–16007PubMedCrossRef

18.

Olumi AF, Grossfeld GD, Hayward SW et al (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed

19.

Kojima Y, Acar A, Eaton EN et al (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Nat Acad Sci USA 107(46):20009–20014PubMedCrossRef

20.

Studebaker AW, Storci G, Werbeck JL et al (2008) Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68(21):9087–9095PubMedCrossRef

21.

Rudnick JA, Arendt LM, Klebba I et al (2011) Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS ONE 6(9):e24605PubMedCrossRef

22.

Ronnov-Jessen L, Petersen OW, Koteliansky VE et al (1995) The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 95(2):859–873PubMedCrossRef

23.

Liu R, Li H, Liu L et al (2012) Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 13(3):123–129PubMedCrossRef

24.

Wolf BB, Quan C, Tran T et al (2008) On the edge of validation: cancer protease fibroblast activation protein. Mini Rev Med Chem 8(7):719–727PubMedCrossRef

25.

Lee J, Fassnacht M, Nair S et al (2005) Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 65(23):11156–11163PubMedCrossRef

26.

Scanlan MJ, Raj BK, Calvo B et al (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Nat Acad Sci USA 91(12):5657–5661PubMedCrossRef

27.

Park JE, Lenter MC, Zimmermann RN et al (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274(51):36505–36512PubMedCrossRef

28.

Huang Y, Simms AE, Mazur A et al (2011) Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 28(6):567–579PubMedCrossRef

29.

LeBeau AM, Brennen WN, Aggarwal S et al (2009) Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther 8(5):1378–1386PubMedCrossRef

30.

Loeffler M, Kruger JA, Niethammer AG et al (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116(7):1955–1962PubMedCrossRef

31.

Tahtis K, Lee FT, Wheatley JM et al (2003) Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther 2(8):729–737PubMed

32.

Sotgia F, Martinez-Outschoorn UE, Howell A et al (2012) Caveolin-1 and Cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 7:423–467PubMedCrossRef

33.

Koo JS, Park S, Kim SI et al (2011) The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol 32(4):787–799PubMedCrossRef

34.

Witkiewicz AK, Dasgupta A, Sammons S et al (2010) Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 10(2):135–143PubMedCrossRef

35.

Witkiewicz AK, Dasgupta A, Sotgia F et al (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174(6):2023–2034PubMedCrossRef

36.

Witkiewicz AK, Kline J, Queenan M et al (2011) Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 10(11):1794–1809PubMedCrossRef

37.

Goetz JG, Minguet S, Navarro-Lerida I et al (2011) Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146(1):148–163PubMedCrossRef

38.

Guttery DS, Shaw JA, Lloyd K et al (2010) Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev 29(4):595–606PubMedCrossRef

39.

Howeedy AA, Virtanen I, Laitinen L et al (1990) Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Investig 63(6):798–806PubMed

40.

Lightner VA, Marks JR, McCachren SS (1994) Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Exp Cell Res 210(2):177–184PubMedCrossRef

41.

Kawakatsu H, Shiurba R, Obara M et al (1992) Human carcinoma cells synthesize and secrete tenascin in vitro. Jpn J Cancer Res 83(10):1073–1080PubMedCrossRef

42.

Hancox RA, Allen MD, Holliday DL et al (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11(2):R24PubMedCrossRef

43.

Dandachi N, Hauser-Kronberger C, More E et al (2001) Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 193(2):181–189PubMedCrossRef

44.

Jahkola T, Toivonen T, Nordling S et al (1998) Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer 34(11):1687–1692PubMedCrossRef

45.

Jahkola T, Toivonen T, Virtanen I et al (1998) Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 78(11):1507–1513PubMedCrossRef

46.

Suwiwat S, Ricciardelli C, Tammi R et al (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10(7):2491–2498PubMedCrossRef

47.

Jahkola T, Toivonen T, von Smitten K et al (1996) Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 69(6):445–447PubMedCrossRef

48.

Oskarsson T, Acharyya S, Zhang XH et al (2011) Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17(7):867–874PubMedCrossRef

49.

Minn AJ, Gupta GP, Padua D et al (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Nat Acad Sci USA 104(16):6740–6745PubMedCrossRef

50.

Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518–524PubMedCrossRef

51.

Nakahara H, Gabazza EC, Fujimoto H et al (2006) Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 36(12):3334–3345PubMedCrossRef

52.

Midwood K, Sacre S, Piccinini AM et al (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15(7):774–780PubMedCrossRef

53.

Houghton J, Wang TC (2005) Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128(6):1567–1578PubMedCrossRef

54.

Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103–113PubMedCrossRef

55.

Park EJ, Lee JH, Yu GY et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2):197–208PubMedCrossRef

56.

de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5):411–423PubMedCrossRef

57.

Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285–296PubMedCrossRef

58.

Okayasu I, Ohkusa T, Kajiura K et al (1996) Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39(1):87–92PubMedCrossRef

59.

DeNardo DG, Barreto JB, Andreu P et al (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2):91–102PubMedCrossRef

60.

Tan W, Zhang W, Strasner A et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548–553PubMedCrossRef

61.

Yang L, Huang J, Ren X et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+ CD11b+ myeloid cells that promote metastasis. Cancer Cell 13(1):23–35PubMedCrossRef

62.

Doedens AL, Stockmann C, Rubinstein MP et al (2010) Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 70(19):7465–7475PubMedCrossRef

63.

Mahmoud SM, Lee AH, Paish EC et al (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159–163PubMedCrossRef

64.

Mahmoud SM, Lee AH, Paish EC et al (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132(2):545–553PubMedCrossRef

65.

Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955PubMedCrossRef

66.

Ruffell B, Au A, Rugo HS et al (2011) Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 109(8):2796–2801PubMedCrossRef

67.

Denardo DG, Brennan DJ, Rexhepaj E et al (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54–67PubMedCrossRef

68.

Menard S, Tomasic G, Casalini P et al (1997) Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3(5):817–819PubMed

69.

Calabro A, Beissbarth T, Kuner R et al (2009) Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116(1):69–77PubMedCrossRef

70.

Mukhtar RA, Nseyo O, Campbell MJ et al (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11(1):91–100PubMedCrossRef

71.

Lee AH, Happerfield LC, Bobrow LG et al (1997) Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 50(8):669–673PubMedCrossRef

72.

Campbell MJ, Tonlaar NY, Garwood ER et al (2011) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128(3):703–711PubMedCrossRef

73.

Leek RD, Lewis CE, Whitehouse R et al (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56(20):4625–4629PubMed

74.

Lin EY, Li JF, Gnatovskiy L et al (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66(23):11238–11246PubMedCrossRef

75.

Fujimoto H, Sangai T, Ishii G et al (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125(6):1276–1284PubMedCrossRef

76.

Tsutsui S, Yasuda K, Suzuki K et al (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14(2):425–431PubMed

77.

Bolat F, Kayaselcuk F, Nursal TZ et al (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 25(3):365–372PubMed

78.

Gottfried E, Kunz-Schughart LA, Weber A et al (2008) Expression of CD68 in non-myeloid cell types. Scand J Immunol 67(5):453–463PubMedCrossRef

79.

Meric JB, Rottey S, Olaussen K et al (2006) Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59(1):51–64PubMedCrossRef

80.

Ricciotti E, Fitzgerald GA (2010) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31(5):986–1000CrossRef

81.

Denkert C, Winzer KJ, Muller BM et al (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97(12):2978–2987PubMedCrossRef

82.

Boland GP, Butt IS, Prasad R et al (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90(2):423–429PubMedCrossRef

83.

Wulfing P, Diallo R, Muller C et al (2003) Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129(7):375–382PubMedCrossRef

84.

Denkert C, Winzer KJ, Hauptmann S (2004) Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 4(6):428–433PubMedCrossRef

85.

Hu M, Peluffo G, Chen H et al (2009) Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Nat Acad Sci USA 106(9):3372–3377PubMedCrossRef

86.

Howe LR, Chang SH, Tolle KC et al (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65(21):10113–10119PubMedCrossRef

87.

Perrone G, Santini D, Vincenzi B et al (2005) COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 46(5):561–568PubMedCrossRef

88.

Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Nat Cancer Inst 102(9):627–637PubMedCrossRef

89.

Radisky DC, Santisteban M, Berman HK et al (2011) p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) 4(12):1953–1960CrossRef

90.

Yang WT, Lewis MT, Hess K et al (2010) Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305–314PubMedCrossRef

91.

Hu M, Yao J, Carroll DK et al (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13(5):394–406PubMedCrossRef

92.

Baglole CJ, Ray DM, Bernstein SH et al (2006) More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest 35(3–4):297–325PubMedCrossRef

93.

Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6(2):130–140PubMedCrossRef

94.

Butcher DT, Alliston T, Weaver VM (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9(2):108–122PubMedCrossRef

95.

DuFort CC, Paszek MJ, Weaver VM (2011) Balancing forces: architectural control of mechanotransduction. Nat Rev Mol Cell Biol 12(5):308–319PubMedCrossRef

96.

Weaver VM, Petersen OW, Wang F et al (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137(1):231–245PubMedCrossRef

97.

Paszek MJ, Zahir N, Johnson KR et al (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8(3):241–254PubMedCrossRef

98.

Huang S, Ingber DE (2005) Cell tension, matrix mechanics, and cancer development. Cancer Cell 8(3):175–176PubMedCrossRef

99.

Provenzano PP, Inman DR, Eliceiri KW et al (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11PubMedCrossRef

100.

Erler JT, Bennewith KL, Nicolau M et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222–1226PubMedCrossRef

101.

Kirschmann DA, Seftor EA, Nieva DR et al (1999) Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res Treat 55(2):127–136PubMedCrossRef

102.

Peyrol S, Raccurt M, Gerard F et al (1997) Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol 150(2):497–507PubMed

103.

Kuperwasser C, Chavarria T, Wu M et al (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101(14):4966–4971PubMedCrossRef

104.

Levental KR, Yu H, Kass L et al (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906PubMedCrossRef

105.

Decitre M, Gleyzal C, Raccurt M et al (1998) Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab Invest 78(2):143–151PubMed

106.

Barry-Hamilton V, Spangler R, Marshall D et al (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16(9):1009–1017PubMedCrossRef

107.

Hu M, Yao J, Cai L et al (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37(8):899–905PubMedCrossRef

108.

Campbell I, Polyak K, Haviv I (2009) Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res 69(17):6765–6768 discussion 9PubMedCrossRef

109.

Enkelmann A, Heinzelmann J, von Eggeling F et al (2011) Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol 137(5):751–759PubMedCrossRef

110.

Fiegl H, Millinger S, Goebel G et al (2006) Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66(1):29–33PubMedCrossRef

111.

Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5(15):1597–1601PubMedCrossRef

112.

Jiang L, Gonda TA, Gamble MV et al (2008) Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 68(23):9900–9908PubMedCrossRef

113.

Ronnov-Jessen L, Petersen OW (1993) Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68(6):696–707PubMed

114.

Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13(1):7–12PubMedCrossRef

115.

Krenning G, Zeisberg EM, Kalluri R (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225(3):631–637PubMedCrossRef

116.

Bechtel W, McGoohan S, Zeisberg EM et al (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16(5):544–550PubMedCrossRef

117.

Cheng N, Chytil A, Shyr Y et al (2007) Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 67(10):4869–4877PubMedCrossRef

118.

Bhowmick NA, Chytil A, Plieth D et al (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303(5659):848–851PubMedCrossRef

119.

Trimboli AJ, Cantemir-Stone CZ, Li F et al (2009) Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461(7267):1084–1091PubMedCrossRef

120.

Fazi F, Nervi C (2008) MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res 79(4):553–561PubMedCrossRef

121.

Gangaraju VK, Lin H (2009) MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 10(2):116–125PubMedCrossRef

122.

Leung AK, Sharp PA (2006) Function and localization of microRNAs in mammalian cells. Cold Spring Harb Symp Quant Biol 71:29–38PubMedCrossRef

123.

Tiscornia G, Izpisua Belmonte JC (2010) MicroRNAs in embryonic stem cell function and fate. Genes Dev 24(24):2732–2741PubMedCrossRef

124.

Davis BN, Hata A (2010) microRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer 1(11):1100–1114CrossRef

125.

Farazi TA, Horlings HM, Ten Hoeve JJ et al (2011) MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71(13):4443–4453PubMedCrossRef

126.

Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706PubMedCrossRef

127.

Iliopoulos D, Jaeger SA, Hirsch HA et al (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39(4):493–506PubMedCrossRef

128.

Iorio MV, Ferracin M, Liu CG et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065–7070PubMedCrossRef

129.

Jazbutyte V, Thum T (2010) MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 11(8):926–935PubMedCrossRef

130.

Davis BN, Hilyard AC, Lagna G et al (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454(7200):56–61PubMedCrossRef

131.

Liu G, Friggeri A, Yang Y et al (2010) miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207(8):1589–1597PubMedCrossRef

132.

Thum T, Gross C, Fiedler J et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224):980–984PubMedCrossRef

133.

Yao Q, Cao S, Li C et al (2011) Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer 128(8):1783–1792PubMedCrossRef

134.

Lu Z, Liu M, Stribinskis V et al (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31):4373–4379PubMedCrossRef

135.

Song B, Wang C, Liu J et al (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29:29PubMedCrossRef

136.

Zhu S, Wu H, Wu F et al (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18(3):350–359PubMedCrossRef

137.

Qian B, Katsaros D, Lu L et al (2008) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 117(1):131–140PubMedCrossRef

138.

Farmer P, Bonnefoi H, Anderle P et al (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15(1):68–74PubMedCrossRef

139.

Ostermann E, Garin-Chesa P, Heider KH et al (2008) Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 14(14):4584–4592PubMedCrossRef

Titel: Stromal biomarkers in breast cancer development and progression
verfasst von: Jenny A. Rudnick
Charlotte Kuperwasser
Publikationsdatum: 01.10.2012
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 7/2012
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-012-9499-8

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Stromal biomarkers in breast cancer development and progression

Abstract

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging

Erratum to: Progression of cutaneous melanoma: implications for treatment

Sentinel lymph node biopsy versus selective neck dissection for detection of metastatic oral squamous cell carcinoma

Systematic, evidence-based discovery of biomarkers at the NCI

Biomarkers of cancer metastasis through the lymphovascular system: future perspectives

Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie